Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer

Authors

  • Lama Abujamous Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar; Office of Vice President for Research and Graduate Studies, Qatar University, Doha, Qatar
  • Abderrezzaq Soltani Office of Vice President for Medical and Health Sciences, Qatar University, Doha, Qatar; Department of Clinical Pharmacy and Practice, College of Pharmacy, QU Health, Qatar University, Doha, Qatar
  • Hamda Al-Thawadi Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar
  • Abdelali Agouni Office of Vice President for Research and Graduate Studies, Qatar University, Doha, Qatar; Department of Clinical Pharmacy and Practice, College of Pharmacy, QU Health, Qatar University, Doha, Qatar

DOI:

https://doi.org/10.17305/bb.2023.9757

Keywords:

Ovarian carcinomas, combination therapy, PARP inhibitors, immune checkpoint inhibitors, nanomedicine

Abstract

Advanced ovarian cancer is a malignancy that spreads beyond the ovaries to the pelvis, abdomen, lungs, or lymph nodes. Effective treatment options are available to improve survival rates in patients with advanced ovarian cancer. These include radiation, surgery, chemotherapy, immunotherapy, and targeted therapy. Drug resistance, however, remains a significant challenge in pharmacotherapeutic interventions, leading to reduced efficacy and unfavorable patient outcomes. Combination therapy, which involves using multiple drugs with different mechanisms of action at their optimal dose, is a promising approach to circumvent this challenge and it involves using multiple drugs with different mechanisms of action at their optimal dose. In recent years, nanotechnology has emerged as a valuable alternative for enhancing drug delivery precision and minimize toxicity. Nanoparticles can deliver drugs to specific cancer cells, resulting in higher drug concentrations at the tumor site, and reducing overall drug toxicity. Nanotechnology-based drug delivery systems have the potential to improve the therapeutic effects of anti-cancer drugs, reduce drug resistance, and improve outcomes for patients with advanced ovarian cancer. This literature review aims to examine the current understanding of combining poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapy in treating advanced ovarian cancer and the potential impact of nanotechnology on drug delivery.

Downloads

Download data is not yet available.
Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer

Downloads

Published

11-03-2024

Issue

Section

Reviews

Categories

How to Cite

1.
Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer. Biomol Biomed [Internet]. 2024 Mar. 11 [cited 2024 Apr. 18];24(2):230–237. Available from: https://bjbms.org/ojs/index.php/bjbms/article/view/9757